Cargando…

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140

Successful vaccine development against HIV will likely require the induction of strong, long-lasting humoral and cellular immune responses in both the systemic and mucosal compartments. Based on the known immunological linkage between the upper-respiratory and urogenital tracts, we explored the pote...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arias, Mauricio A., Van Roey, Griet A., Tregoning, John S., Moutaftsi, Magdalini, Coler, Rhea N., Windish, Hillarie P., Reed, Steven G., Carter, Darrick, Shattock, Robin J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400629/ https://www.ncbi.nlm.nih.gov/pubmed/22829921 http://dx.doi.org/10.1371/journal.pone.0041144

Ejemplares similares

Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
por: Coler, Rhea N., et al.
Publicado: (2011)

Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice
por: Van Roey, Griet A, et al.
Publicado: (2012)

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
por: Cauwelaert, Natasha Dubois, et al.
Publicado: (2016)

Computer-Aided Approaches for Targeting HIVgp41
por: Allen, William J., et al.
Publicado: (2012)

Antigen-specific T lymphocyte responses elicited by a DNA – MVA HIV CN54gp140 immunization regime are significantly altered by the TLR4 adjuvant GLA
por: McKay, PF, et al.
Publicado: (2012)

P19-54 LB. Interrogating the membrane-proximal external region (MPER) of HIV-1 gp140
por: Jeffs, S, et al.
Publicado: (2009)

Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen
por: Arias, Mauricio A., et al.
Publicado: (2011)

Glucopyranosyl Lipid A Adjuvant Significantly Enhances HIV Specific T and B Cell Responses Elicited by a DNA-MVA-Protein Vaccine Regimen
por: McKay, Paul F., et al.
Publicado: (2014)

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
por: Coler, Rhea N., et al.
Publicado: (2018)

Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice
por: Buffa, Viviana, et al.
Publicado: (2012)

Molecular and Cellular Response Profiles Induced by the TLR4 Agonist-Based Adjuvant Glucopyranosyl Lipid A
por: Lambert, Stacie L., et al.
Publicado: (2012)

Schistosoma mansoni antigen Sm-p80: prophylactic efficacy using TLR4 agonist vaccine adjuvant glucopyranosyl lipid A-Alum in murine and non-human primate models
por: Zhang, Weidong, et al.
Publicado: (2018)

A “Prime-Pull” Vaccine Strategy Has a Modest Effect on Local and Systemic Antibody Responses to HIV gp140 in Mice
por: Tregoning, John S., et al.
Publicado: (2013)

Mucosal Application of gp140 Encoding DNA Polyplexes to Different Tissues Results in Altered Immunological Outcomes in Mice
por: Mann, Jamie F. S., et al.
Publicado: (2013)

The adjuvant GLA-AF enhances human intradermal vaccine responses
por: Carter, Darrick, et al.
Publicado: (2018)

A structure-function approach to optimizing TLR4 ligands for human vaccines
por: Carter, Darrick, et al.
Publicado: (2016)

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE
por: Coler, Rhea N, et al.
Publicado: (2015)

HIVgp120 activates autoreactive CD4-specific T cell responses by unveiling of hidden CD4 peptides during processing
Publicado: (1995)

Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model
por: Kwon, Kee Woong, et al.
Publicado: (2019)

TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes
por: McKay, Paul F., et al.
Publicado: (2016)

Evolution of Matrix Gla and Bone Gla Protein Genes in Jawed Vertebrates
por: Leurs, Nicolas, et al.
Publicado: (2021)

A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93
por: Orr, Mark T., et al.
Publicado: (2014)

First Total Synthesis of 5′-O-α-d-Glucopyranosyl Tubercidin
por: Ouyang, Wenliang, et al.
Publicado: (2020)

Toll-Like Receptor 4 Expression on Lymphoma Cells Is Critical for Therapeutic Activity of Intratumoral Therapy With Synthetic TLR4 Agonist Glucopyranosyl Lipid A
por: Lu, Hailing, et al.
Publicado: (2020)

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design
por: Viegas, Edna O., et al.
Publicado: (2018)

Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice
por: Paes, Wayne, et al.
Publicado: (2016)

Anomeric Spironucleosides of β-d-Glucopyranosyl Uracil as Potential Inhibitors of Glycogen Phosphorylase
por: Stathi, Aggeliki, et al.
Publicado: (2019)

Arachidonic Acid Cascade and Eicosanoid Production Are Elevated While LTC4 Synthase Modulates the Lipidomics Profile in the Brain of the HIVgp120-Transgenic Mouse Model of NeuroHIV
por: Yuan, Nina Y., et al.
Publicado: (2022)

GLA-AF, an Emulsion-Free Vaccine Adjuvant for Pandemic Influenza
por: Clegg, Christopher H., et al.
Publicado: (2014)

Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial
por: Joachim, Agricola, et al.
Publicado: (2016)

A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7
por: Fox, Christopher B, et al.
Publicado: (2014)

Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
por: Choi, Yu Hwa, et al.
Publicado: (2023)

Matrix Gla protein in tumoral pathology
por: GHEORGHE, SIMONA ROXANA, et al.
Publicado: (2016)

Development of the Sm14/GLA-SE Schistosomiasis Vaccine Candidate: An Open, Non-Placebo-Controlled, Standardized-Dose Immunization Phase Ib Clinical Trial Targeting Healthy Young Women
por: Santini-Oliveira, Marília, et al.
Publicado: (2022)

Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms
por: Donnelly, Louise, et al.
Publicado: (2011)

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines
por: Van Hoeven, Neal, et al.
Publicado: (2017)

2-O-α-D-Glucopyranosyl-l-ascorbic acid as an antitumor agent for infusion therapy
por: Miura, Kaori, et al.
Publicado: (2017)

Straightforward Synthesis of Novel 1-(2′-α-O-D-Glucopyranosyl ethyl) 2-Arylbenzimidazoles
por: Arumugam, Natarajan, et al.
Publicado: (2012)

Clinical Adjuvant Combinations Stimulate Potent B-Cell Responses In Vitro by Activating Dermal Dendritic Cells
por: Matthews, Katie, et al.
Publicado: (2013)

Synthesis of New Series of 2-C-(β-D-glucopyranosyl)-Pyrimidines and Their Evaluation as Inhibitors of Some Glycoenzymes
por: Szennyes, Eszter, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hj8v8qbtvmccik9nh69oir5frj